<DOC>
	<DOC>NCT02083575</DOC>
	<brief_summary>role of Vit C to Augment iron chelation with DFP or DFX in thalassemic patients.</brief_summary>
	<brief_title>Role of Vitamin C to Augment Iron Chelation With DFP or DFX</brief_title>
	<detailed_description>assess safety and efficacy of Vit C to Augment iron chelation with DFP or DFX in thalassemic patients.</detailed_description>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Deferiprone</mesh_term>
	<mesh_term>Chelating Agents</mesh_term>
	<criteria>• Subjects with overload secondary to thalassemia major • with HIV positive or have active HCV. A history of serious immunologic hypersensitivity to any medication such as anaphylaxis or angioedema. Participation in a previous investigational drug study within the 30 days preceding screening. A woman of childbearing potential must have a negative serum pregnancy test at screening. She must use a medically acceptable form of birth control during the study and for a month afterwards who are pregnant or breastfeeding. An inability to adhere to the designated procedures and restrictions of this protocol.</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>vitamin c</keyword>
	<keyword>thalassemia major</keyword>
	<keyword>iron chelation</keyword>
</DOC>